Association between depression and brain tumor: a systematic review and meta-analysis

Abstract

BackgroundPatients with brain tumor are in risk of depression or depressive symptoms, but the estimated prevalence varies between studies. The aim of this study is to get a proper summarized estimate of depression prevalence in brain tumor patients.MethodsLiterature search on Pubmed, PsycINFO, and Cochrane library from January 1981 through October 2016. The prevalence of depression or depressive symptoms in brain tumor patients was estimated by screening scales and analyzed using stratified meta-analysis and subgroup analysis. The prevalence of depression level or symptoms during the follow-up periods was detected by secondary analysis.ResultsAmong the 37 studies included in this meta-analysis, 25 used a cross-sectional design and 12 used longitudinal study. The pooled prevalence was 21.7% (971/4518 individuals, 95 % confidence interval (CI) 18.2%–25.2%) for overall sample. Lower prevalence was detected in studies with sample size ≥100 than <100, lower grade tumor than high grade tumor, studies using clinician-rated depression scales than self-rated or non-depression-specific ones, and in patients from UK, Germany and Italy than USA. After analyzing 6 longitudinal studies, prevalence of depression remained no change in the follow-up periods. No significant differences were observed between study designs and tumor types.ConclusionsThe estimated prevalence of depression or depressive symptoms among brain tumor patients was 21.7%, affected by depression assessment type, sample size, tumor grade and country. Diagnosis and treatment of co-morbid depression in brain tumor patients need to be addressed in future studies for better life quality and oncology management.

Depression and Quality of Life in Patients with Neurological Disorder in a Malaysian Hospital

“…17 Depression was prevalent among patients with brain tumour around the time of diagnosis or treatment. 18 The prevalence of depression among primary brain tumour patients has been reported to be 2.5% to 15.4%, 12 and as much as 44% among all brain tumour patients. 19 A study in Taiwan found that the prevalence of depression among patients with cancer was 20%.…”

Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model

“…Psychiatric disorders, such as schizophrenia, bipolar disorder, and depression, are extremely heritable complex polygenetic neurodevelopmental disorders ( 1 , 35 – 38 ). Despite the large market for new psychiatric drug therapies that already exist, the drug discovery for treating psychiatric disorders is stagnant ( 7 , 8 ).…”

Cognitive functioning following brain irradiation as part of cancer treatment: Characterizing better cognitive performance

“…30 Additionally, the high intercorrelation between fatigue and depression in our findings suggests that interventions to reduce symptoms of depression may be also beneficial. Depression is prevalent in approximately 22% of brain tumor survivors 32 and is associated with cognitive impairment and other health risks (eg, overall survival and suicide risk). 33 However, it should be noted that median levels of depression in our sample were in the minimal/no depression to mild range and that the clinical cutoff for depression (PHQ ≥ 10) did not significantly differ between groups.…”